You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 2, 2024

United States: These 47 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in the United States

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "United States: These 47 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SPRAVATO (esketamine hydrochloride) generic drug versions launch?

Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SPRAVATO is a drug marketed by Janssen Pharms. There are six patents protecting this drug.

This drug has forty patent family members in nineteen countries.

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this generic product. Additional details are available on the esketamine hydrochloride profile page.

When can PHEXXI (citric acid; lactic acid; potassium bitartrate) generic drug versions launch?

Generic name: citric acid; lactic acid; potassium bitartrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 06, 2024
Generic Entry Controlled by: United States Patent Patent 6,706,276

Drug Price Trends for PHEXXI
PHEXXI is a drug marketed by Evofem Inc. There are four patents protecting this drug.

This drug has sixty-five patent family members in twenty-three countries.

See drug price trends for PHEXXI.

The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.

When can EXPAREL (bupivacaine) generic drug versions launch?

Generic name: bupivacaine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXPAREL is a drug marketed by Pacira Pharms Inc. There are ten patents protecting this drug.

This drug has seven patent family members in four countries. There has been litigation on patents covering EXPAREL

See drug price trends for EXPAREL.

The generic ingredient in EXPAREL is bupivacaine. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bupivacaine profile page.

When can IONSYS (fentanyl hydrochloride) generic drug versions launch?

Generic name: fentanyl hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 01, 2024
Generic Entry Controlled by: United States Patent Patent 6,975,902

IONSYS is a drug marketed by The Medicines Co. There are eight patents protecting this drug.

This drug has eighty-nine patent family members in eighteen countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. Additional details are available on the fentanyl hydrochloride profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2024
Generic Entry Controlled by: United States Patent Patent 11,278,544

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-nine patent family members in forty-four countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can NATROBA (spinosad) generic drug versions launch?

Generic name: spinosad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for NATROBA
NATROBA is a drug marketed by Parapro Llc. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-eight countries.

See drug price trends for NATROBA.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the spinosad profile page.

When can RYDAPT (midostaurin) generic drug versions launch?

Generic name: midostaurin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RYDAPT is a drug marketed by Novartis. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in twenty-seven countries. There has been litigation on patents covering RYDAPT

See drug price trends for RYDAPT.

The generic ingredient in RYDAPT is midostaurin. One supplier is listed for this generic product. Additional details are available on the midostaurin profile page.

When can TRALEMENT (cupric sulfate; manganese sulfate; selenious acid; zinc sulfate) generic drug versions launch?

Generic name: cupric sulfate; manganese sulfate; selenious acid; zinc sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRALEMENT is a drug marketed by Am Regent. There is one patent protecting this drug.

This drug has six patent family members in six countries.

See drug price trends for TRALEMENT.

The generic ingredient in TRALEMENT is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this generic product. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.

When can RADICAVA (edaravone) generic drug versions launch?

Generic name: edaravone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 05, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RADICAVA is a drug marketed by Mitsubishi Tanabe. There are four patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has six patent family members in six countries.

See drug price trends for RADICAVA.

The generic ingredient in RADICAVA is edaravone. One supplier is listed for this generic product. Additional details are available on the edaravone profile page.

When can OMONTYS (peginesatide acetate) generic drug versions launch?

Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2024
Generic Entry Controlled by: United States Patent Patent 7,084,245

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

When can ULESFIA (benzyl alcohol) generic drug versions launch?

Generic name: benzyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2024
Generic Entry Controlled by: United States Patent Patent 7,294,342

ULESFIA is a drug marketed by Shionogi Inc. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering ULESFIA

The generic ingredient in ULESFIA is benzyl alcohol. There are fifty drug master file entries for this API. Additional details are available on the benzyl alcohol profile page.

When can ADASUVE (loxapine) generic drug versions launch?

Generic name: loxapine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: United States Patent Patent 9,370,629

ADASUVE is a drug marketed by Alexza Pharms. There are five patents protecting this drug.

This drug has two hundred and twenty-seven patent family members in twenty-one countries. There has been litigation on patents covering ADASUVE

See drug price trends for ADASUVE.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the loxapine profile page.

When can CHILDREN'S ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) generic drug versions launch?

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: United States Patent Patent 10,238,640

CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

When can GLEOLAN (aminolevulinic acid hydrochloride) generic drug versions launch?

Generic name: aminolevulinic acid hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GLEOLAN is a drug marketed by Nxdc.

This drug has nine patent family members in eight countries.

See drug price trends for GLEOLAN.

The generic ingredient in GLEOLAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aminolevulinic acid hydrochloride profile page.

When can ILEVRO (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2024
Generic Entry Controlled by: United States Patent Patent 7,947,295

Drug Price Trends for ILEVRO
ILEVRO is a drug marketed by Harrow Eye. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

When can VYLEESI (AUTOINJECTOR) (bremelanotide acetate) generic drug versions launch?

Generic name: bremelanotide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYLEESI (AUTOINJECTOR) is a drug marketed by Palatin Technologies. There are five patents protecting this drug.

This drug has eighty patent family members in twenty-six countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this generic product. Additional details are available on the bremelanotide acetate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 29, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

When can ENDARI (l-glutamine) generic drug versions launch?

Generic name: l-glutamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ENDARI is a drug marketed by Emmaus Medcl. One tentatively approved generic is ready to enter the market.

This drug has forty-six patent family members in thirty-one countries.

See drug price trends for ENDARI.

The generic ingredient in ENDARI is l-glutamine. There are forty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the l-glutamine profile page.

When can DALVANCE (dalbavancin hydrochloride) generic drug versions launch?

Generic name: dalbavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DALVANCE is a drug marketed by Abbvie. There are four patents protecting this drug.

This drug has fifty-eight patent family members in twenty countries.

See drug price trends for DALVANCE.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the dalbavancin hydrochloride profile page.

When can KIMYRSA (oritavancin diphosphate) generic drug versions launch?

Generic name: oritavancin diphosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KIMYRSA is a drug marketed by Melinta Therap. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

See drug price trends for KIMYRSA.

The generic ingredient in KIMYRSA is oritavancin diphosphate. One supplier is listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

When can ORBACTIV (oritavancin diphosphate) generic drug versions launch?

Generic name: oritavancin diphosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ORBACTIV is a drug marketed by Melinta Therap. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

See drug price trends for ORBACTIV.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 10, 2024
Generic Entry Controlled by: United States Patent Patent 7,056,927

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie. There are seven patents protecting this drug.

This drug has fifty-six patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

When can ORILISSA (elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 10, 2024
Generic Entry Controlled by: United States Patent Patent 7,056,927

Drug Price Trends for ORILISSA
ORILISSA is a drug marketed by Abbvie. There are ten patents protecting this drug.

This drug has ninety-eight patent family members in twenty-six countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

When can SOMATULINE DEPOT (lanreotide acetate) generic drug versions launch?

Generic name: lanreotide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SOMATULINE DEPOT is a drug marketed by Ipsen Pharma.

This drug has ninety-eight patent family members in twenty-six countries.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lanreotide acetate profile page.

When can SUSTOL (granisetron) generic drug versions launch?

Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: United States Patent Patent 8,715,710

SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.

This drug has eighteen patent family members in ten countries.

See drug price trends for SUSTOL.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

When can PRIALT (ziconotide acetate) generic drug versions launch?

Generic name: ziconotide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 01, 2024
Generic Entry Controlled by: United States Patent Patent 5,364,842

PRIALT is a drug marketed by Tersera. There are three patents protecting this drug.

This drug has six patent family members in four countries.

See drug price trends for PRIALT.

The generic ingredient in PRIALT is ziconotide acetate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ziconotide acetate profile page.

When can ASCOR (ascorbic acid) generic drug versions launch?

Generic name: ascorbic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 02, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ASCOR is a drug marketed by Mcguff.

This drug has six patent family members in four countries.

See drug price trends for ASCOR.

The generic ingredient in ASCOR is ascorbic acid. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ascorbic acid profile page.

When can FLUORODOPA F18 (fluorodopa f-18) generic drug versions launch?

Generic name: fluorodopa f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 10, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

FLUORODOPA F18 is a drug marketed by Feinstein.

This drug has six patent family members in four countries.

The generic ingredient in FLUORODOPA F18 is fluorodopa f-18. One supplier is listed for this generic product. Additional details are available on the fluorodopa f-18 profile page.

When can DEFENCATH (heparin sodium; taurolidine) generic drug versions launch?

Generic name: heparin sodium; taurolidine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2024
Generic Entry Controlled by: United States Patent Patent 8,541,393

DEFENCATH is a drug marketed by Cormedix. There are four patents protecting this drug.

This drug has fourteen patent family members in eight countries.

The generic ingredient in DEFENCATH is heparin sodium; taurolidine. There are seventy-seven drug master file entries for this API. Additional details are available on the heparin sodium; taurolidine profile page.

When can BYETTA (exenatide synthetic) generic drug versions launch?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for BYETTA
BYETTA is a drug marketed by Astrazeneca Ab.

This drug has fourteen patent family members in eight countries. There has been litigation on patents covering BYETTA

See drug price trends for BYETTA.

The generic ingredient in BYETTA is exenatide synthetic. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the exenatide synthetic profile page.

When can EXEM FOAM KIT (air polymer-type a) generic drug versions launch?

Generic name: air polymer-type a
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXEM FOAM KIT is a drug marketed by Giskit. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in EXEM FOAM KIT is air polymer-type a. There are thirty-seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the air polymer-type a profile page.

When can NOURIANZ (istradefylline) generic drug versions launch?

Generic name: istradefylline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2024
Generic Entry Controlled by: United States Patent Patent 7,541,363

NOURIANZ is a drug marketed by Kyowa Kirin. There are four patents protecting this drug.

This drug has sixty-three patent family members in eighteen countries.

See drug price trends for NOURIANZ.

The generic ingredient in NOURIANZ is istradefylline. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the istradefylline profile page.

When can MACRILEN (macimorelin acetate) generic drug versions launch?

Generic name: macimorelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MACRILEN is a drug marketed by Novo. There is one patent protecting this drug.

This drug has eleven patent family members in ten countries.

See drug price trends for MACRILEN.

The generic ingredient in MACRILEN is macimorelin acetate. One supplier is listed for this generic product. Additional details are available on the macimorelin acetate profile page.

When can XARELTO (rivaroxaban) generic drug versions launch?

Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for XARELTO
XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Five tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

When can RYALTRIS (mometasone furoate; olopatadine hydrochloride) generic drug versions launch?

Generic name: mometasone furoate; olopatadine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 13, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for RYALTRIS
RYALTRIS is a drug marketed by Glenmark Specialty. There are fourteen patents protecting this drug.

This drug has eighty-eight patent family members in thirty-two countries.

See drug price trends for RYALTRIS.

The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. There are thirty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.

When can SANCUSO (granisetron) generic drug versions launch?

Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 22, 2025
Generic Entry Controlled by: United States Patent Patent 7,608,282

Drug Price Trends for SANCUSO
SANCUSO is a drug marketed by Cumberland. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in thirty-one countries. There has been litigation on patents covering SANCUSO

See drug price trends for SANCUSO.

The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

When can DUAKLIR PRESSAIR (aclidinium bromide; formoterol fumarate) generic drug versions launch?

Generic name: aclidinium bromide; formoterol fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: United States Patent Patent RE46417

DUAKLIR PRESSAIR is a drug marketed by Covis. There are four patents protecting this drug.

This drug has one hundred and fifty-six patent family members in forty-six countries.

See drug price trends for DUAKLIR PRESSAIR.

The generic ingredient in DUAKLIR PRESSAIR is aclidinium bromide; formoterol fumarate. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the aclidinium bromide; formoterol fumarate profile page.

When can TUDORZA PRESSAIR (aclidinium bromide) generic drug versions launch?

Generic name: aclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: United States Patent Patent RE46417

TUDORZA PRESSAIR is a drug marketed by Covis. There are four patents protecting this drug.

This drug has one hundred and fifty-six patent family members in forty-six countries.

See drug price trends for TUDORZA PRESSAIR.

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the aclidinium bromide profile page.

When can PIZENSY (lactitol) generic drug versions launch?

Generic name: lactitol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 12, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PIZENSY is a drug marketed by Braintree Labs. There is one patent protecting this drug.

The generic ingredient in PIZENSY is lactitol. There are four drug master file entries for this API. Additional details are available on the lactitol profile page.

When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch?

Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2025
Generic Entry Controlled by: United States Patent Patent 10,947,544

IZERVAY is a drug marketed by Iveric Bio. There are eight patents protecting this drug.

This drug has ninety-eight patent family members in twenty-seven countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

When can IXEMPRA KIT (ixabepilone) generic drug versions launch?

Generic name: ixabepilone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: United States Patent Patent 7,312,237

IXEMPRA KIT is a drug marketed by R-pharm Us Llc. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-six countries.

See drug price trends for IXEMPRA KIT.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ixabepilone profile page.

When can BARHEMSYS (amisulpride) generic drug versions launch?

Generic name: amisulpride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BARHEMSYS is a drug marketed by Acacia. There are five patents protecting this drug.

This drug has sixty-eight patent family members in twenty-seven countries.

See drug price trends for BARHEMSYS.

The generic ingredient in BARHEMSYS is amisulpride. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the amisulpride profile page.

When can JUXTAPID (lomitapide mesylate) generic drug versions launch?

Generic name: lomitapide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: United States Patent Patent 8,618,135

JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

When can SMOFLIPID 20% (fish oil; medium chain triglycerides; olive oil; soybean oil) generic drug versions launch?

Generic name: fish oil; medium chain triglycerides; olive oil; soybean oil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SMOFLIPID 20% is a drug marketed by Fresenius Kabi Usa.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.

When can XELSTRYM (dextroamphetamine) generic drug versions launch?

Generic name: dextroamphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

XELSTRYM is a drug marketed by Noven Pharms Inc. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in twelve countries. There has been litigation on patents covering XELSTRYM

See drug price trends for XELSTRYM.

The generic ingredient in XELSTRYM is dextroamphetamine. There are eighteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dextroamphetamine profile page.

When can TLANDO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TLANDO is a drug marketed by Antares Pharma Inc. There are twelve patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-six patent family members in fifteen countries.

See drug price trends for TLANDO.

The generic ingredient in TLANDO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can EDURANT (rilpivirine hydrochloride) generic drug versions launch?

Generic name: rilpivirine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2025
Generic Entry Controlled by: United States Patent Patent 7,125,879

Drug Price Trends for EDURANT
EDURANT is a drug marketed by Janssen Prods. There are three patents protecting this drug.

This drug has one hundred and ninety-nine patent family members in forty-two countries. There has been litigation on patents covering EDURANT

See drug price trends for EDURANT.

The generic ingredient in EDURANT is rilpivirine hydrochloride. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the rilpivirine hydrochloride profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.